Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2010-04-27 | Partner, PricewaterhouseCoopers LLP (1980-2002); Director, Idera Pharmaceuticals, Inc. (since 2002); Director, Synta Pharmaceuticals Corp. (since 2004); Director, Oscient Pharmaceuticals Corporation (since 2003). |
| 2011-06-08 | Mr. Reardon is a Life Science audit partner at PricewaterhouseCooper with an MBA from Harvard Business School. |
| 2018-04-18 | Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP provides each Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. |
| 2019-04-15 | Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies. |
| 2020-04-14 | Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP... He serves on the Valuation Committee and as Chair of the Audit Committee of each Fund. |
| 2021-04-13 | Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP... He holds an MBA from Harvard Business School and a BA in East Asian History from Harvard College. |
Data sourced from SEC filings. Last updated: 2025-07-01